What a Hospital Rankings List and a PBM Hearing Reveal About Modern Medicine’s Hidden Business Model

The strange thing about healthcare is that the most important numbers are often not clinical

What if the biggest force shaping your medical bill is not your doctor, your diagnosis, or even your insurance plan, but a layered business system that turns care into a competition for revenue? That is the uncomfortable thread connecting two seemingly different scenes: a public ranking of health systems by total net operating revenue, and a congressional hearing focused on pharmacy benefit managers. One looks like accounting. The other looks like policy theater. Together, they point to a deeper truth: American healthcare is increasingly organized as a financial relay race, not a healing system.

That matters because once a sector starts measuring success primarily in dollars, the most powerful players are no longer the ones closest to patients. They are the ones who can control flows, set rules, and capture spreads between what gets paid in and what gets paid out. In healthcare, this creates a strange inversion. The more essential the service becomes, the more it can be pulled into a maze of intermediaries, consolidated systems, and opaque incentives.

The question underneath both headlines is not just who is making money. It is: what happens to medicine when scale becomes a proxy for power and complexity becomes a business model?

---

Revenue is not the same as value, but in healthcare it often gets treated that way

A ranking by total net operating revenue sounds neutral, even objective. It feels like a scoreboard. But in healthcare, revenue can be a misleading trophy. A large system may have enormous operating revenue because it owns many hospitals, dominates a region, or has negotiated prices that smaller systems cannot match. None of that automatically means it delivers better outcomes, lower costs, or better access.

Think of two grocery stores. One has a massive checkout line because it serves the whole city and charges premium prices. The other is smaller, local, and efficient. If you ranked them only by revenue, you might conclude the first is “better.” But the number tells you almost nothing about whether customers are healthier, happier, or better served. Healthcare is even more distorted, because patients rarely choose like ordinary consumers. They are constrained by emergencies, insurance networks, referrals, and geography.

This is where revenue becomes a signal of market position more than care quality. Large systems can use their size to negotiate higher reimbursement, buy physician practices, acquire competitors, and bundle services in ways that make their financial scale self-reinforcing. The number on the ranking is not just an accounting metric. It is a footprint of power.

In healthcare, the biggest organizations are often not simply the best at treating people. They are the best at navigating, shaping, and monetizing the system around treatment.

That distinction is crucial, because it explains why healthcare can feel simultaneously expensive, fragmented, and impersonal even as some institutions grow richer. Scale does not automatically produce simplicity. Often it produces layering, and layering is where opacity begins.

---

PBMs are the perfect example of how healthcare learned to profit from complexity

If hospital revenue shows us the size of the machine, pharmacy benefit managers show us the machine’s hidden gears. PBMs sit between drug manufacturers, insurers, pharmacies, employers, and patients. In theory, they negotiate lower drug prices and streamline benefits. In practice, the system can become so opaque that no one involved sees the full chain of incentives clearly.

This is the central paradox: the very entities meant to reduce costs can become cost multipliers if they profit from the spread between list prices, rebates, reimbursements, and formularies. A patient may walk into a pharmacy expecting one copay, only to discover that the “negotiated” price, the rebate, and the reimbursement logic are all operating on different planes. The result is not just frustration. It is distrust.

PBMs are not unique in this respect. They are simply one of the purest expressions of a broader design principle in modern healthcare: when money moves through enough hands, the system can become more profitable precisely because it is harder to understand.

Consider the analogy of a package delivery route. If one driver picks up a parcel and delivers it directly, the process is transparent. If the package passes through six warehouses, gets relabeled, repackaged, and billed at each stage, the customer may not even know where delays or charges originated. PBMs often function like those warehouses, except the package is a prescription and the stakes are life-changing.

The hearing is important not simply because it scrutinizes one intermediary. It matters because it exposes a structural pattern: healthcare has evolved into a set of toll roads. Hospitals, insurers, PBMs, specialty pharmacies, and health systems all claim to add value. Some do. Some do not. But the more layers the system adds, the easier it becomes to extract rent without clearly improving care.

---

The deeper tension: healthcare rewards coordination, but markets reward fragmentation

At first glance, this seems like a problem of bad actors or weak regulation. It is deeper than that. Healthcare is trapped between two competing logics.

On one side, medicine requires coordination. A patient with diabetes may need a primary care physician, an endocrinologist, a pharmacist, lab tests, nutrition support, and a system that tracks medications over time. Fragmentation harms patients because disease does not arrive in neat silos.

On the other side, markets reward specialization and division. Every handoff creates an opportunity for a fee, a margin, a rebate, or a contract term. Every intermediary can justify itself as solving a problem created by the previous intermediary. The system therefore evolves toward complexity even when everyone says they want simplicity.

This is why healthcare reform so often disappoints. It tends to attack symptoms, not structure. If the real problem is that the system profits from opacity, then simply asking people to be more informed is not enough. Patients cannot negotiate what they cannot see. Doctors cannot optimize what they do not control. Employers cannot manage what is hidden inside rebate formulas and contractual black boxes.

A useful way to think about this is through three layers:

1. Clinical layer: what care is actually needed.
2. Operational layer: who delivers it, where, and how.
3. Financial layer: how each actor gets paid.

Most debates focus on the clinical layer, because that is where the moral language lives. But the financial layer quietly shapes the operational layer, which in turn constrains the clinical layer. If the financial incentives reward consolidation, then hospitals merge. If they reward formulary manipulation, then PBMs gain leverage. If they reward complexity, then complexity spreads.

In healthcare, the payment system is not downstream from care. It is the architecture of care.

That is the key insight linking a revenue ranking and a PBM hearing. One reveals who has become large enough to dominate the architecture. The other reveals how the architecture itself is monetized.

---

The real scarcity in healthcare is not money, it is intelligibility

Most healthcare debates are framed as cost problems. Costs are real, of course. But cost is often the symptom of a deeper scarcity: intelligibility. When patients cannot tell who sets the price, when employers cannot trace where their dollars go, and when even clinicians cannot understand the rules governing prescriptions, the system ceases to behave like a service and starts behaving like a fog machine.

Fog is profitable. In fog, the people with maps win.

That is why consolidation and intermediation often travel together. Large health systems can use their size to simplify some parts of the patient experience while making the overall market harder to navigate. PBMs can claim administrative efficiency while embedding hidden revenue streams. The public experiences the system as both centralized and fragmented, which is not a contradiction. It is the business model.

Here is the uncomfortable insight: the system does not merely tolerate complexity, it increasingly selects for it. Complexity protects margins. It blunts accountability. It makes comparison difficult. And when comparison becomes difficult, the best-positioned actors can define what counts as normal.

This also explains why the word “transparency” often disappoints in healthcare. Transparency without simplification can become information overload. A price file no ordinary person can interpret is not transparency, it is decoration. True intelligibility means a patient, employer, pharmacist, or doctor can answer basic questions without needing a second industry just to decode the first one.

Imagine trying to buy a house where the agent, lender, inspector, title company, and moving company each secretly controlled part of the final price, and none were required to disclose the full chain. That is not a market. It is a coordination trap. In many ways, healthcare has normalized exactly that kind of trap.

---

What would a healthier system optimize for?

If revenue and intermediary power are poor stand-ins for value, what should a serious healthcare system optimize for instead? Not just lower prices. Not just larger institutions. The real targets should be legibility, continuity, and accountability.

Legibility means people can understand how the system works without insider knowledge. Patients should know why a medication costs what it costs, why a referral is needed, and who is benefiting from the transaction.

Continuity means care is designed around the patient’s journey, not the institution’s convenience. The system should reduce handoffs that add no clinical value.

Accountability means every major actor can be evaluated against outcomes that matter, not just transaction volume or revenue growth.

These three ideas create a very different definition of excellence. A hospital system is not great because it is large. A PBM is not valuable because it is powerful. A healthcare organization is valuable if it makes the system easier to navigate, not harder.

This is where the most promising reforms often start: not with broad moral statements, but with targeted redesigns that cut out unnecessary friction. For example, standardizing drug pricing explanations, simplifying formularies, requiring clearer pass-through of rebates, or separating administrative services from revenue extraction. The point is not to abolish scale or coordination. The point is to make scale answerable to care.

There is a lesson here for employers, policymakers, and consumers alike. When evaluating a healthcare arrangement, ask a deceptively simple question: does this structure reduce confusion, or does it profit from it? That single question reveals more than many pages of pricing data.

---

Key Takeaways

1. Do not confuse revenue with value. Large health systems may dominate financially without delivering proportionally better care.
2. Intermediaries often profit from opacity. If a process is hard to trace, someone may be earning from the confusion.
3. The core problem is structural, not just moral. Healthcare incentives often reward complexity, consolidation, and hidden spreads.
4. Transparency is not enough unless it creates intelligibility. Information must be usable by patients, employers, and clinicians.
5. Ask whether a system reduces friction or monetizes it. That question cuts through most healthcare branding.

---

The future of healthcare will be decided by who controls the map

The most important battle in healthcare is not simply over prices, and not even over regulation. It is over legibility. Whoever controls the map controls the journey, and whoever controls the journey can decide where value gets captured along the way.

That is why a revenue ranking and a PBM hearing belong in the same conversation. One shows the size of the players. The other shows the hidden channels through which they operate. Together, they reveal a system that has become astonishingly skilled at turning care into a sequence of billable abstractions.

The final question is not whether healthcare can be made cheaper in the abstract. It is whether it can be made understandable enough that costs, incentives, and outcomes line up again. Until then, the system will keep rewarding those who are best at navigating the maze, not those who are best at healing.

And that is the real scandal. Not simply that healthcare is expensive, but that it has become difficult to tell what, exactly, you are paying for.